Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
Volume: 39, Issue: 15_suppl, Pages: 3574 - 3574
Published: May 20, 2021
Abstract
3574 Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantly associated with increased systemic exposure of irinotecan’s active metabolite SN-38 and subsequently severe irinotecan-associated adverse-events (AEs) including (febrile) neutropenia and diarrhea. Severe AEs may lead to hospitalization, loss of...
Paper Details
Title
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
Published Date
May 20, 2021
Journal
Volume
39
Issue
15_suppl
Pages
3574 - 3574
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History